Myocardial Infarction Market Report 2026

The myocardial infarction market size has grown strongly in recent years. It will grow from $2.19 billion in 2025 to $2.36 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to rise in smoking prevalence, increasing cases of hypertension, high ldl levels in population, limited access to early cardiac screening, sedentary lifestyle habits.

The myocardial infarction market size is expected to see strong growth in the next few years. It will grow to $3.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to advancement in cardiac drug formulations, growing adoption of telecardiology, rising investment in cardiology r&d, increasing use of ai for cardiac diagnosis, expansion of emergency cardiac care infrastructure. Major trends in the forecast period include increasing adoption of advanced cardiac rehabilitation programs, growing use of combination drug therapies for post-mi care, rising emphasis on early detection and prevention of heart attacks, expanding use of minimally invasive procedures in acute mi management, increasing focus on lifestyle modification and long-term risk reduction.

The rising incidence of cardiovascular diseases is expected to propel the growth of the myocardial infarction market going forward. Cardiovascular diseases encompass disorders affecting the heart and blood vessels, with myocardial infarction drug classes playing a key role in managing these conditions, particularly in addressing complications after heart attacks. For instance, in September 2024, according to the British Heart Foundation, a UK-based cardiovascular research charity, approximately 7.6 million people in the UK were affected by heart and circulatory diseases, including around 4 million men and 3.6 million women. These conditions account for roughly 27% of all deaths in the UK, resulting in over 170,000 deaths annually, or about 480 deaths per day, equivalent to one death every three minutes. Therefore, the rising prevalence of cardiovascular diseases is driving the myocardial infarction market.

Major companies in the myocardial infarction market are focusing on developing novel drugs, such as anti-inflammatory therapies, to provide targeted treatment for cardiovascular inflammation and gain a competitive edge. Anti-inflammatory drugs reduce inflammation by modulating the body’s immune response, alleviating pain and vascular damage. For example, in June 2023, Agepha Pharma, a Slovakia-based medical product manufacturer, received FDA approval for Lodoco (colchicine), the first anti-inflammatory drug designed to target the underlying cause of atherosclerotic cardiovascular disease. Lodoco aims to lower the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients and can be used alongside cholesterol-lowering medications. Clinical trials demonstrated a 31% reduction in the overall risk of cardiovascular death, myocardial infarction, stroke, or coronary revascularization with Lodoco.

In March 2024, Novo Nordisk, a Denmark-based provider of diabetes and cardiovascular therapies, acquired Cardior Pharmaceuticals for approximately €1.025 billion ($1.11 billion). This strategic acquisition strengthens Novo Nordisk’s cardiovascular portfolio by adding advanced RNA-targeting therapeutics and accelerating the development of first-in-class therapies for post-myocardial-infarction heart failure. Cardior Pharmaceuticals, a Germany-based biotechnology company, specializes in RNA-based therapeutics, including its lead microRNA-targeting candidate, CDR132L, aimed at treating heart failure following myocardial infarction.

Major companies operating in the myocardial infarction market are Pfizer Inc, Johnson & Johnson Services Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca PLC, Boehringer Ingelheim GmbH, Daiichi Sankyo Co Ltd, Apotex Inc, Par Pharmaceutical Companies Inc, Amgen Inc, Merck & Co Inc, Takeda Pharmaceutical Company Ltd, Gilead Sciences Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Ltd, Lupin Ltd, United Therapeutics Corporation, CSPC Pharmaceutical Group Ltd, Zhejiang Huahai Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd.

North America was the largest region in the myocardial infarction market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial infarction market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myocardial infarction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on imported cardiac drugs and interventional devices have increased manufacturing and procurement costs in the myocardial infarction market, particularly in regions that rely heavily on imported stents and diagnostic tools. These tariffs slow down the widespread adoption of advanced treatment technologies and raise prices in hospital and retail pharmacy channels. However, they also encourage domestic production of cost-effective cardiac devices and stimulate regional innovation in manufacturing capabilities.

The myocardial infarction market research report is one of a series of new reports that provides myocardial infarction market statistics, including myocardial infarction industry global market size, regional shares, competitors with a myocardial infarction market share, detailed myocardial infarction market segments, market trends and opportunities, and any further data you may need to thrive in the myocardial infarction industry. This myocardial infarction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Myocardial infarction is a potentially life-threatening condition that occurs when the blood supply to the heart muscle is suddenly blocked, leading to tissue damage. It is often triggered by high levels of low-density lipoprotein (LDL) cholesterol, high blood pressure, and smoking.

The main drug classes used in the treatment of myocardial infarction include antiplatelet agents, glycoprotein IIB/IIIA inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers, analgesics, and thrombolytics. Antiplatelet agents are drugs that reduce the blood’s ability to form clots by preventing platelets from aggregating. These medications can be administered orally or via injection and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The myocardial infarction market consists of sales of heparin, bivalirudin, and enoxaparin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.